Q2 2026 saw revenues rise 4% YoY and 32% QoQ to SEK 702 million, with operating margin at 42% and cash at SEK 4.1 billion. Buvidal and Brixadi posted strong growth, while R&D and US expansion remain key priorities. Full-year guidance was reiterated.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.